BlueRock Therapeutics Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
487
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$582M
BlueRock Therapeutics General Information
Description
Developer of a new generation of authentic and engineered cell therapies created to impact various diseases. The company develops induced pluripotent stem cell therapies to cure a range of diseases with the help of regenerative medicines across neurology, cardiology and immunology indications, thus enabling healthcare professionals to deliver advanced care and ensure fast recovery of the patients suffering from intractable diseases.
Contact Information
Website
www.bluerocktx.com(Operating Subsidiary)
Corporate Office
- 238 Main Street, 3rd Floor
- Cambridge, MA 02142
- United States
Corporate Office
- 238 Main Street, 3rd Floor
- Cambridge, MA 02142
- United States
BlueRock Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 20-Sep-2019 | $582M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 12-Dec-2016 | Completed | Startup |
BlueRock Therapeutics Comparisons
Industry
Financing
Details
BlueRock Therapeutics Competitors (53)
One of BlueRock Therapeutics’s 53 competitors is Tranquis Therapeutics, a Venture Capital-Backed company based in Palo Alto, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tranquis Therapeutics | Venture Capital-Backed | Palo Alto, CA | ||||
| Casma Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| AltPep | Venture Capital-Backed | Seattle, WA | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY |
BlueRock Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BlueRock Therapeutics Patents
BlueRock Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026161533-A1 | Compositions and methods for determining the concentration of live cells in a population of cells comprising cell aggregates | Pending | 23-Jan-2025 | ||
| WO-2026136161-A1 | Method of measuring retinal sensitivity | Pending | 20-Dec-2024 | ||
| WO-2026117659-A1 | Methods of treating inherited retinal diseases | Pending | 27-Nov-2024 | ||
| US-20260146229-A1 | Photoreceptor precursor cell (prp) compositions and uses thereof | Pending | 27-Nov-2024 | ||
| WO-2026117660-A1 | Photoreceptor precursor cell (prp) compositions and uses thereof | Pending | 27-Nov-2024 | C12N5/062 |
BlueRock Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BlueRock Therapeutics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Leaps by Bayer | Corporate Venture Capital | Minority | ||
| Versant Ventures | Venture Capital | Minority |
BlueRock Therapeutics FAQs
-
When was BlueRock Therapeutics founded?
BlueRock Therapeutics was founded in 2016.
-
Where is BlueRock Therapeutics headquartered?
BlueRock Therapeutics is headquartered in Cambridge, MA.
-
What is the size of BlueRock Therapeutics?
BlueRock Therapeutics has 487 total employees.
-
What industry is BlueRock Therapeutics in?
BlueRock Therapeutics’s primary industry is Drug Discovery.
-
Is BlueRock Therapeutics a private or public company?
BlueRock Therapeutics is a Private company.
-
What is the current valuation of BlueRock Therapeutics?
The current valuation of BlueRock Therapeutics is .
-
What is BlueRock Therapeutics’s current revenue?
The current revenue for BlueRock Therapeutics is .
-
How much funding has BlueRock Therapeutics raised over time?
BlueRock Therapeutics has raised $225M.
-
Who are BlueRock Therapeutics’s investors?
Leaps by Bayer and Versant Ventures have invested in BlueRock Therapeutics.
-
Who are BlueRock Therapeutics’s competitors?
Tranquis Therapeutics, Casma Therapeutics, Sangamo Therapeutics, AltPep, and Prevail Therapeutics are some of the 53 competitors of BlueRock Therapeutics.
-
When was BlueRock Therapeutics acquired?
BlueRock Therapeutics was acquired on 20-Sep-2019.
-
Who acquired BlueRock Therapeutics?
BlueRock Therapeutics was acquired by Bayer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
